Sermorelin vs CJC-1295: Which & Why

Sermorelin and CJC-1295 are two of the most commonly compared growth-hormone peptides, and on a quick read they look almost interchangeable: both are growth-hormone-releasing hormone (GHRH) analogs, both nudge your own pituitary to release growth hormone (GH) instead of injecting GH directly, and both are sold off-label through compounding pharmacies rather than as FDA-approved finished drugs. The meaningful differences are not about which one "works better" — neither has a modern outcome trial proving it changes how you sleep, recover, or age. The real differences are pharmacological (how long each lingers in the body) and regulatory (how each is made, and how grey the supply chain gets). This guide separates the mechanism from the proof.

The one-sentence version

Sermorelin is a short-acting GHRH(1-29) peptide cleared within minutes; CJC-1295 is a longer-acting GHRH analog engineered to resist breakdown — and in its "with DAC" form it can stimulate GH and IGF-1 for days from a single injection¹. Both are compounded and off-label, and neither has a robust human trial showing real-world benefit. If you remember one thing, remember that the choice between them is mostly a choice about half-life, not about proven results.

Same pathway, different molecules

Both peptides target the GHRH receptor on the pituitary, prompting your body's own pulsatile GH release — which in turn raises insulin-like growth factor 1 (IGF-1). Sermorelin is GHRH(1-29): the shortest fragment of natural GHRH that still retains full GH-releasing activity. That makes it biologically faithful to the hormone your body already uses, but also fragile — like native GHRH, it is degraded quickly in the bloodstream, so its action is brief.

CJC-1295 is a modified GHRH(1-29) analog built specifically to survive longer. It carries amino-acid substitutions that resist the enzyme (DPP-IV) that chews up GHRH, and — in the "with DAC" (Drug Affinity Complex) version — a chemical group that binds to albumin in your blood so the peptide circulates for days instead of minutes. In healthy adults, single doses of CJC-1295 raised GH for up to about six days and IGF-1 for up to about nine to eleven days, with mean IGF-1 staying elevated for over a week at the higher doses¹. That is the entire design goal: fewer injections, a flatter and more sustained signal.

An important nuance often blurred in marketing: "CJC-1295" is sometimes sold without DAC (a version also called modified GRF 1-29), which behaves much more like sermorelin — short-acting, cleared quickly. The dramatic multi-day profile belongs specifically to CJC-1295 with DAC. If a product just says "CJC-1295," you may not actually know which one you are getting, which is itself part of the grey-market problem below.

What the human evidence actually shows

Here is the honest core of the comparison: for both peptides, the human evidence is thin and built on blood markers, not outcomes.

For sermorelin, the most-cited supporting study gave GHRH(1-29) as single nightly injections to healthy elderly men and showed it raised GH and IGF-1² — a genuine pharmacological signal, but a small, short, marker-based study, not a trial of how people slept, recovered, or felt. Sermorelin's other firmly-documented role is diagnostic: GHRH(1-29) was used as a provocative test of pituitary GH reserve³. There is no modern, large randomized trial showing sermorelin improves body composition, sleep quality, or "healthy aging" outcomes.

For CJC-1295, the human evidence is even more limited. The pivotal study is essentially a pharmacokinetic and safety report: it established that the analog raises GH and IGF-1 for an extended period and was generally well tolerated over the short term in healthy volunteers¹. It was not a trial of muscle, recovery, sleep, fat loss, or longevity. So when you compare the two on "what's proven," you are comparing one short, old marker study against one short pharmacokinetic study — neither tells you that the peptide will deliver the benefits it's marketed for.

Why does GH even decline with age, the premise these peptides lean on? GH secretion genuinely falls with advancing age and with greater visceral fat⁴ — that part is real physiology. But "GH falls with age" plus "this peptide raises GH short-term" does not equal "this peptide reverses aging." That leap is the marketing, not the evidence. The closest controlled signal for a GHRH analog affecting an aging-related outcome comes from a trial in older adults that found cognitive effects alongside raised IGF-1⁵ — but that was investigational research on a specific analog, not an approval or proof for sermorelin or CJC-1295. We hold that line throughout our pillar guide to sermorelin's sleep and recovery evidence.

Regulatory status: both off-label, both compounded, and CJC-1295 is greyer

Neither sermorelin nor CJC-1295 is an FDA-approved finished drug today. Sermorelin once had an approved brand (Geref), discontinued in the mid-2000s for commercial reasons; it is now compounded and prescribed off-label. CJC-1295 never had FDA approval as a marketed medicine at all — it appears in the literature as an investigational compound and, increasingly, as a doping-control and "research chemical" analyte.

That last point matters for safety. CJC-1295 shows up prominently in anti-doping and forensic literature: methods have been developed specifically to confirm CJC-1295 abuse⁶, it features in broader work on detecting synthetic GHRH analogs⁷, and analyses of online doping markets document how peptides like it are traded through unregulated internet forums⁸. Translated out of journal language: a meaningful share of the CJC-1295 supply is grey-market, sold as "research chemicals not for human use," with no guarantee of identity, purity, dose, or sterility. Sermorelin obtained through a licensed compounding pharmacy with a prescription sits on firmer ground than a vial bought from a peptide website — but compounded does not mean FDA-approved, and the long-term human safety data for either peptide is sparse.

Safety and monitoring: shared class cautions

Because both work through the GH/IGF-1 axis, they share the same monitoring priorities a prescriber would track: IGF-1 levels and glucose handling, since raising GH/IGF-1 can affect insulin sensitivity. The longer action of CJC-1295 with DAC is a double-edged feature: convenient, but it also means a sustained, non-pulsatile elevation of IGF-1 rather than the brief, natural pulses sermorelin produces — and the long-term consequences of that flatter, days-long signal in healthy people simply have not been studied in proper trials. Anyone weighing either peptide should treat it as a prescription decision with medical monitoring, not a supplement. For how dosing is actually approached and why "as prescribed" is the only defensible answer, see our evidence review of sermorelin dosing.

Which, and why

If you and a qualified prescriber decide a GHRH analog is appropriate, the practical trade-off looks like this. Sermorelin offers a short, pulsatile, more physiologic signal and the longer (if still modest) track record, at the cost of frequent dosing. CJC-1295 — specifically with DAC — offers convenience and a sustained signal from far fewer injections, at the cost of a flatter, less natural IGF-1 profile, essentially no long-term human safety data, and a supply chain that skews grey-market. Neither is proven to deliver better sleep, recovery, or healthy-aging outcomes, because the outcome trials don't exist for either one.

For a strictly sleep-and-recovery, healthy-aging goal — the lane this site covers — sermorelin's shorter, bedtime-friendly pulsatile action and its (relatively) better-documented prescription pathway make it the more defensible starting point of the two, while being honest that "more defensible" still means off-label and largely unproven. If you're comparing GHRH analogs more broadly, see how sermorelin stacks up against the ghrelin-receptor peptide ipamorelin in sermorelin vs ipamorelin, and against the FDA-approved analog tesamorelin in tesamorelin vs sermorelin. And if you want to see how the clinics and pharmacies offering these peptides compare on prescribing standards, oversight, and price, we rank them in our guide to the best sermorelin providers.

The bottom line

Sermorelin and CJC-1295 engage the same GHRH pathway, so the choice between them is not really about potency — it's about half-life and supply integrity. Sermorelin is short-acting, compounded, off-label, with old marker-level human data. CJC-1295 (with DAC) is engineered to last days, has only a pharmacokinetic-level human study behind it, and circulates heavily as a grey-market research chemical. Both raise GH and IGF-1; neither is proven to improve real-world sleep, recovery, or aging. Compare them on the evidence, treat either as a monitored prescription decision, and don't mistake a longer half-life for a stronger result.